Literature DB >> 12708970

Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide.

Ruud P M Dings1, Monica M Arroyo, Nathan A Lockwood, Loes I van Eijk, Judy R Haseman, Arjan W Griffioen, Kevin H Mayo.   

Abstract

Anginex is a designed peptide 33mer that functions as a cytokine-like agent to inhibit angiogenesis. Although this short linear peptide has been shown by NMR and CD to form a nascent beta-sheet conformation in solution, the actual bioactive structure formed upon binding to its receptor on the surface of endothelial cells could be quite different. By using a series of double-cysteine disulphide-bridged analogues, we provide evidence in the present study that the beta-sheet is in fact the bioactive conformation of anginex. CD and NMR spectral analysis of the analogues indicate formation of a beta-sheet conformation. Three functional assays, endothelial cell proliferation, apoptosis and in vitro angiogenesis, were performed on all analogues. As long as the placement of disulphide bonds preserved the beta-strand alignment, as in the proposed bioactive conformation, bioactivities were preserved. Knowledge of the bioactive conformation of anginex will aid in the design of smaller molecule mimetics of this potent anti-angiogenic peptide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12708970      PMCID: PMC1223486          DOI: 10.1042/BJ20030295

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  The structure of mouse tumour-necrosis factor at 1.4 A resolution: towards modulation of its selectivity and trimerization.

Authors:  K J Baeyens; H L De Bondt; A Raeymaekers; W Fiers; C J De Ranter
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-04

Review 2.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

Authors:  A W Griffioen; G Molema
Journal:  Pharmacol Rev       Date:  2000-06       Impact factor: 25.468

3.  SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.

Authors:  N Guex; M C Peitsch
Journal:  Electrophoresis       Date:  1997-12       Impact factor: 3.535

4.  NMR structure of a de novo designed, peptide 33mer with two distinct, compact beta-sheet folds.

Authors:  E Ilyina; V Roongta; K H Mayo
Journal:  Biochemistry       Date:  1997-04-29       Impact factor: 3.162

5.  Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density.

Authors:  R Wild; S Ramakrishnan; J Sedgewick; A W Griffioen
Journal:  Microvasc Res       Date:  2000-05       Impact factor: 3.514

Review 6.  The antiangiogenic properties of bactericidal/permeability-increasing protein (BPI).

Authors:  Daisy W J van der Schaft; John Wagstaff; Kevin H Mayo; Arjan W Griffioen
Journal:  Ann Med       Date:  2002       Impact factor: 4.709

7.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

8.  Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution.

Authors:  E Hohenester; T Sasaki; B R Olsen; R Timpl
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

9.  Effect of culture conditions on endothelial cell growth and responsiveness.

Authors:  I A Relou; C A Damen; D W van der Schaft; G Groenewegen; A W Griffioen
Journal:  Tissue Cell       Date:  1998-10       Impact factor: 2.466

10.  Designed beta-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities.

Authors:  K H Mayo; J Haseman; E Ilyina; B Gray
Journal:  Biochim Biophys Acta       Date:  1998-09-16
View more
  14 in total

1.  Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative activity and cellular internalization.

Authors:  Hyun Sook Hwang; Dong Won Kim; Soung Soo Kim
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

2.  Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Authors:  Ruud P M Dings; Nigam Kumar; Michelle C Miller; Melissa Loren; Huzaifa Rangwala; Thomas R Hoye; Kevin H Mayo
Journal:  J Pharmacol Exp Ther       Date:  2012-12-11       Impact factor: 4.030

3.  Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature.

Authors:  Maria E Akerman; Jan Pilch; David Peters; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-01       Impact factor: 11.205

4.  Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay.

Authors:  Morikazu Amano; Minoru Suzuki; Satoshi Andoh; Hajime Monzen; Kaoru Terai; Brent Williams; Chang W Song; Kevin H Mayo; Takeo Hasegawa; Ruud P M Dings; Robert J Griffin
Journal:  Int J Clin Oncol       Date:  2007-02-25       Impact factor: 3.402

5.  Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy.

Authors:  Samir V Jenkins; Dmitry A Nedosekin; Emily K Miller; Vladimir P Zharov; Ruud P M Dings; Jingyi Chen; Robert J Griffin
Journal:  Int J Hyperthermia       Date:  2017-05-09       Impact factor: 3.914

6.  The anti-angiogenic peptide anginex disrupts the cell membrane.

Authors:  Jan Pilch; Carla M Franzin; Lynn M Knowles; Fernando J Ferrer; Francesca M Marassi; Erkki Ruoslahti
Journal:  J Mol Biol       Date:  2005-12-20       Impact factor: 5.469

7.  Exploring the In situ pairing of human galectins toward synthetic O-mannosylated core M1 glycopeptides of α-dystroglycan.

Authors:  Lareno L Villones; Anna-Kristin Ludwig; Hiroyuki Kumeta; Seiya Kikuchi; Rika Ochi; Tomoyasu Aizawa; Shin-Ichiro Nishimura; Hans-Joachim Gabius; Hiroshi Hinou
Journal:  Sci Rep       Date:  2022-10-23       Impact factor: 4.996

8.  Radiation-induced galectin-1 by endothelial cells: a promising molecular target for preferential drug delivery to the tumor vasculature.

Authors:  Meenakshi Upreti; Azemat Jamshidi-Parsian; Scott Apana; Marc Berridge; Daniel A Fologea; Nathan A Koonce; Ralph L Henry; Robert J Griffin
Journal:  J Mol Med (Berl)       Date:  2012-10-23       Impact factor: 4.599

9.  Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.

Authors:  Ruud P M Dings; Emily S Van Laar; Jeremy Webber; Yan Zhang; Robert J Griffin; Stephen J Waters; John R MacDonald; Kevin H Mayo
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

10.  Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Authors:  Ruud P M Dings; Michelle C Miller; Irina Nesmelova; Lucile Astorgues-Xerri; Nigam Kumar; Maria Serova; Xuimei Chen; Eric Raymond; Thomas R Hoye; Kevin H Mayo
Journal:  J Med Chem       Date:  2012-05-30       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.